Regulatory aspects for Biologic product licensing in India
Journal Title: International Journal of Drug Regulatory Affairs - Year 2019, Vol 7, Issue 1
Abstract
Biologics are the medicinal/ therapeutic/ diagnostic/ preventive preparations composed or derived from living organisms and their spin-off for human use. They include serums, vaccines, antitoxins, blood, antigens and blood components, gene therapy, tissues etc. Biotechnology is used as a unique approach in manufacturing such medicinal agents. The Indian National regulatory authority (CDSCO) is the body that is responsible for manufacturing and import of biological products in India. Biotechnology provides innovative solutions to medical field with more than 200 biologic medicines and vaccines. These developments benefits millions of patients worldwide and more than 600 products under development. At present these products can also be produced by manufacturers other than the innovator, with the expiry of some of patents. These new biotechnological medicines commonly referred to as „similar biologics‟ offer a major opportunity to provide greater access to reasonable healthcare for several lifesaving medicines. India has emerged as one of the leading providers to the world market for „Biosimilars‟. These may be considered to be very essential economical and therapeutical element for the pharmaceutical market in India. The Indian National Regulatory Authority is considered to be responsible for evaluating safety, efficacy and quality of all pharmaceuticals in India. The Department of Biotechnology in India is the department that governs the development, pre-clinical studies of all Biologicals.
Authors and Affiliations
Sanjeev Kumar Maurya, Vikesh Shukla, Prachi Kaushik, SP Yamini Kanti, Anshul Bansal
Keywords
Related Articles
- EP ID EP495687
- DOI 10.22270/ijdra.v7i1.287
- Views 106
- Downloads 0
CURRENT REGULATION OF MEDICAL GASES IN INDIA AND FUTURE ASPECTS
Generally medical gases are administered or supplied directly to the patients. They should be manufactured and transferred with the highest quality possible as per standards and limits decided by the different regulatory...
A comprehensive study of Regulatory compliance for Biosimilars in US, EU and India
The biopharmaceutical industry has gained significant interest in the last decade as the numbers of blockbuster biologic products are losing their patent rights. The regulatory authority is also providing marketing appro...
CONCEPT OF 505 (b) (2) APPLICATION: BENEFITS AND CHALLENGES
A 505(b) (2) application is a new drug application (NDA) delineated in section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.505(b)(2) application is one that one or a lot of the investigations relied upon by the...
Nanoparticles and target Drug delivery for cancer treatment: A Comprehensive review
In the healthcare industry, the biggest challenges are cancer. However, there are several drugs are available for the treatment of cancer. In these treatments cure cancer affecting the collateral toxicity to healthy cell...
QUALITY BY DESIGN- A NEW APPROACH TO DRUG DEVELOPMENT
Quality by design is an essential part of the modern approach to pharmaceutical quality. A new approach to drug development could increase efficiencies, provide regulatory relief and flexibility, and offer important busi...